ACGT Fellow, Dr. Samuel Katz Speaks About Cell & Gene Cancer Research Funding

Alliance for Cancer Gene Therapy fellow, Dr. Samuel Katz at Yale Medical Center, speaks about cell and gene therapies for cancer treatment.

There has been great progress in harnessing a patient’s own immune cells to attack blood cancers. Most protocols use DNA to alter the cells, but the new proteins might also attack healthy tissue. Dr. Katz’s research instead employs RNA, which directs the cells to attack only the cancer and has the added advantage of minimal side effects. In addition, RNA reprogramming is more transient, meaning that after conclusion of treatment, RNA and derivative proteins return to their normal state, which further minimizes possible side effects.

Dr. Katz is working with a mouse model whose immune system has been genetically altered to mirror the human immune system, thereby providing a more accurate picture of how patients will react to these treatments.
……………………………………………………………………………………………….

Alliance for Cancer Gene Therapy is committed to building alliances between philanthropic individuals and organizations, and medical and academic institutions, to promote gene therapy research to combat cancer.

To this end, ACGT will identify, fund and monitor innovative research that meets a rigorous set of scientific standards, and has the potential, in the foreseeable future, to treat cancers of all types.

Through this endeavor, ACGT will educate the public about the potential for cancer gene therapy and facilitate greater collaborations among the scientific community to foster the best possible research and ultimately the best treatment.